title: [Ginsenosides combined with dexamethasone in preventing and treating postembolization syndrome following transcatheter arterial chemoembolization: a randomized, controlled and double-blinded prospective trial].
abstract: OBJECTIVE
  To observe the effect of ginsenosides (GS) and low dose glucocorticoid in preventing and treating the postembolization syndrome following transcatheter arterial chemoembolization (TACE).
  
  
  METHODS
  Eighty patients with primary liver carcinoma were randomly divided into 4 double-blinded groups, with 20 patients in each group. Patients in groups A, B, C, D were treated with placebo, dexamethasone (Dex), GS, Dex and GS, respectively. The changes of clinical symptoms and laboratory tests after TACE were observed.
  
  
  RESULTS
  Dex combined with GS markedly decreased the occurrence ratio and lasting time of the symptoms such as nausea, vomiting, fever and pain, and protected the function of liver as compared with the placebo (P<0.05). Single use of Dex or GS improved some symptoms as compared with the placebo, but it was not as good as the combination of Dex and GS.
  
  
  CONCLUSIONS
  Dex combined with GS can effectively prevent and treat the postembolization syndrome following TACE.
authors.affiliation: Department of Traditional Chinese Medicine, Changhai Hospital, Second Military Medical University, Shanghai 200433, China. ylfeng1975@yahoo.com.cn
authors.forename: Ying-Lu
authors.initials: YL
authors.lastname: Feng
authors.forename: Chang-Quan
authors.initials: CQ
authors.lastname: Ling
authors.forename: De-Zeng
authors.initials: DZ
authors.lastname: Zhu
authors.forename: Chao-Qin
authors.initials: CQ
authors.lastname: Yu
authors.forename: Zhe
authors.initials: Z
authors.lastname: Chen
authors.forename: Bai
authors.initials: B
authors.lastname: Li
mesh_terms: D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage; D002166:Camptothecin / Q000008:administration & dosage; D016461:Chemoembolization, Therapeutic / Q000009:adverse effects*; D003907:Dexamethasone / Q000627:therapeutic use*; D004311:Double-Blind Method; D015251:Epirubicin / Q000008:administration & dosage; D005260:Female; D005472:Fluorouracil / Q000008:administration & dosage; D036145:Ginsenosides / Q000627:therapeutic use*; D006801:Humans; D008113:Liver Neoplasms / Q000628:therapy*; D008297:Male; D008875:Middle Aged; D011446:Prospective Studies; D014839:Vomiting / Q000139:chemically induced / Q000517:prevention & control*
chemical_list: D036145:Ginsenosides; D015251:Epirubicin; D003907:Dexamethasone; D005472:Fluorouracil; D002166:Camptothecin